AsiaNet 83926

Venturis Therapeutics, Inc. Announces its Applications for Four New Patents Related to the Use of Therapeutic Angiogenesis in the Treatment of Illnesses Related to the COVID-19 Virus, as Well as Illnesses Related to Other Viruses

DALLAS, May 6, 2020 /PRNewswire=KYODO JBN/ --

Venturis Therapeutics, Inc. ("VT") today announced it has applied for four

provisional patents related to the treatment and/or prevention of virally

induced illnesses related to the COVID-19 virus, as well as other viruses.

These new patent applications cite the following general areas: heart damage

and virally induced strokes; severe acute respiratory syndrome (SARS);

intestinal dysfunction or intestinal epithelial cell damage; and renal

dysfunction or failure.

During the past several months, the VT team has been reviewing numerous early

reports and data from medical professionals all over the world pertaining to

illnesses related to the damage of epithelial cells and microvascular tissue

caused by the COVID-19 virus. This damage is recorded in patients in multiple

age groups both during and after apparent recovery from the COVID-19 virus and

in patients that have experienced severe or only mild viral symptoms. The

presentation of the virally induced illnesses can include, but is not limited

to, strokes, organ failure, fibrosis, sudden blood clots and cell and tissue

ischemia. VT has many years of experience in the use of therapeutic

angiogenesis in the treatment and regeneration of ischemic and/or damaged

epithelial and microvascular cells and tissue.

VT expects that these new patents, combined with VT's other patents, e.g., our

existing stroke patents, will allow VT to expand its development of current and

breakthrough methods and therapies to treat these life threatening and

distressing conditions in large patient populations. With these proposed and

existing patents, VT seeks to be in the forefront of private sector companies

battling the devastating effects of these diseases.

ABOUT VENTURIS THERAPEUTICS

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein

drug candidates to address diseases such as diabetic wounds, severe coronary

heart disease, peripheral artery disease, erectile dysfunction, stroke, spinal

disc disease, and diseases related to virally induced damage to epithelial

cells and microvascular tissue. The active pharmaceutical ingredient (API) in

our drug candidates is FGF-1, a human protein that stimulates the growth of new

blood vessels, thereby increasing the blood supply to ischemic organs and

tissues.

FORWARD LOOKING STATEMENTS

This news release contains forward looking statements that involve risks and

uncertainties. Actual results and outcomes may differ materially from those

discussed or anticipated. For example, statements regarding expectations for

new research, progress with clinical trials or future business initiatives are

forward looking statements. Factors that might affect actual outcomes include,

but are not limited to, FDA approval of Venturis drug candidates, market

acceptance of Venturis products by customers, new developments in the industry,

future revenues, future expenses, future margins, cash usage, and financial

performance. Additionally, until Venturis is cash flow positive from

operations, the Company is dependent upon raising capital to fund its

operations and met its obligations as they come due. There can be no assurance

that Venturis will be able to raise the necessary capital when needed.

Source: Venturis Therapeutics, Inc.

CONTACT: +1 972-681-9368